Disease · MONDO_0009735
Netherton syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Netherton syndrome. Diseases, record MONDO_0009735. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0009735
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Comèl-Netherton syndrome, Ichthyosis, Netherton Syndrome, NS, bamboo hair syndrome
- Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DUPILUMAB | CHEMBL2108675 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SPESOLIMAB | CHEMBL4297911 | Antibody | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ADALIMUMAB | CHEMBL1201580 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SECUKINUMAB | CHEMBL1743068 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DS-2325A | CHEMBL5095274 | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| PIMECROLIMUS | CHEMBL1200686 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| USTEKINUMAB | CHEMBL1201835 | Antibody | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IL12A | Interleukin-12 | 1 | Interleukin-12 inhibitor | Early phase 1 | https://conductscience.org/library/genes/3592 | Drugs and targets |
| IL12B | Interleukin-12 | 1 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Early phase 1 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL17A | Interleukin-17A | 1 | Interleukin 17A inhibitor | Phase 2 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| IL1RAP | IL36 receptor | 1 | IL36 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/3556 | Drugs and targets |
| IL23A | Interleukin-23 | 1 | Interleukin-23 inhibitor | Early phase 1 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| IL36R | IL36 receptor | 1 | IL36 receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/8808 | Drugs and targets |
| IL4R | Interleukin-4 receptor subunit alpha | 1 | Interleukin-4 receptor subunit alpha antagonist | Phase 2/3 | https://conductscience.org/library/genes/3566 | Drugs and targets |
| TNF | Tumor necrosis factor | 1 | TNF-alpha inhibitor | Phase 2 | https://conductscience.org/library/genes/7124 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05856526 | A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome | Phase 2/3 | 43 | 2026-03-12 | Netherton Syndrome | SPESOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03041038 | The Efficacy and Safety of Secukinumab in Patients With Ichthyoses | Phase 2 | 20 | 2021-08-25 | Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04549792 | An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses | Early phase 1 | 13 | 2025-02-12 | Ichthyosis | USTEKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00208026 | Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome | Phase 1/2 | 3 | 2014-12-12 | Netherton Syndrome | PIMECROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02113904 | Clinical Trial Using Humira in Netherton Syndrome | Phase 2 | 11 | Netherton Syndrome | ADALIMUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04244006 | A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome | Phase 2/3 | 10 | Netherton Syndrome | DUPILUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05979831 | A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome | Phase 1/2 | 9 | Netherton Syndrome | DS-2325A | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0009735
GET https://conductscience.org/api/diseases/v1/MONDO_0009735/drugs